All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
The AML Hub is pleased to present a visual abstract summarizing key results from the non-inferiority phase III ASAP trial comparing sequential conditioning prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) versus salvage chemotherapy followed by allo-HSCT in patients with poor response to first induction or relapsed/refractory acute myeloid leukemia.
The findings from the ASAP trial were recently presented by Schetelig1 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition. The findings suggest that watchful waiting along with sequential conditioning prior to allo-HSCT may improve outcomes in patients with relapsed/refractory acute myeloid leukemia and with a readily available stem cell donor.
To download this visual abstract, click below.Download here
Schetelig J. In patients with relapsed/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia-free survival compared to intensive remission induction chemotherapy followed by allo-HCT: Results from the randomized phase III ASAP trial. Plenary scientific session #4. 64th American Society of Hematology Annual Meeting and Exposition; Dec 11, 2022; New Orleans, US.
Is NGS a useful clinical tool for the risk stratification of patients pre-transplant?
During the 64th ASH Annual Meeting and Exposition, the AML Hub spoke with Ali Bazarbachi, American University of Beirut, Beirut, LB. We asked, Is NGS a useful...
2022 ELN recommendations for the management of AML in adults
A summary of the updated guidelines for the management of AML, from the same publication in Blood, by Döhner et al. on behalf of the ELN.
Subscribe to get the best content related to AML delivered to your inbox